Peptide & Experimental
Modafinil
Wakefulness-promoting medicine (eugeroic, dopamine reuptake inhibitor), approved for narcolepsy, prescription-only · Vigil, Provigil, eugeroic, smart drug
Modafinil is a medicine for the sleep disorder narcolepsy and at the same time one of the best-known smart drugs. People who take it want to stay awake, focused and productive, at university, at work or when traveling. The effect on wakefulness is excellently documented; the boost to the mind in rested people is smaller than its reputation suggests.
In brief
Modafinil promotes wakefulness and is approved as a prescription-only medicine in Germany, in the EU now only for narcolepsy. In large trials it reliably reduced daytime sleepiness, and shift workers had fewer accidents and near-accidents on the way home. In healthy, rested people it improves attention and cognitive performance measurably, but only slightly: a meta-analysis of 19 studies found a small overall effect. It acts via the dopamine system in a way similar to classic stimulants, and rare but serious skin and psychiatric side effects are known. Use for performance enhancement is off-label.
What it is
Modafinil was developed as a wakefulness-promoting agent, in technical terms a eugeroic. In the US it has been approved since 1998 for excessive sleepiness in narcolepsy, and since 2004 also for obstructive sleep apnea and shift work disorder. In Germany it had already been on the market for ten years by 2008, known under the brand name Vigil. After a review in 2011, the European Medicines Agency restricted the approval to narcolepsy in adults. It cited serious skin reactions, psychiatric side effects and cardiovascular risks, and found that modafinil was frequently prescribed outside its indication.
Outside medicine, modafinil has a reputation as a thinking pill. It is taken by students and people with long working days, usually without a diagnosis, and part of the supply comes from the gray market. It is precisely this use that is not approved.
How it is supposed to work
For a long time, modafinil was considered a wakefulness agent that works differently from amphetamine and methylphenidate. A PET study in 10 healthy men corrected this in 2009. After 200 and 400 mg, modafinil occupied 53.8 percent of the dopamine transporters in the caudate nucleus and 47.2 percent in the putamen. As a result, free dopamine rose, including in the nucleus accumbens, the brain’s reward center. The authors see this as a potential for abuse in vulnerable people.
Dopamine is not the only lever. Modafinil also raises catecholamines in the cerebral cortex and acts indirectly on orexin, histamine, glutamate and serotonin, while the inhibitory messenger GABA decreases. Orexin and histamine are central wakefulness signals. This mix explains why many users find modafinil less stimulating than amphetamine. In the narcolepsy trials it did not disturb night-time sleep. The effective half-life after repeated intake is about 15 hours.
What users report
In the biohacking scene, modafinil is valued for long work phases, exams and jet lag. Many describe a calm, focused state without nervousness; others complain of headache, restlessness or poor sleep the following night. These are uncontrolled user reports. The studies partly match them: headache is the most common side effect, and the effect is clearer in more complex tasks than in simple tests.
What is well supported
The effect on wakefulness is excellently documented. In two large double-blind trials with 283 and 271 people with narcolepsy, modafinil reduced daytime sleepiness over 9 weeks, measured with objective tests such as the Multiple Sleep Latency Test. The effect persisted in the open-label follow-up over 40 weeks, and after stopping, sleepiness returned, without withdrawal as seen with amphetamine. In shift workers with a sleep disorder, symptoms improved in 74 percent versus 36 percent on placebo.
Modafinil also works in healthy people, only less strongly. A systematic review found better executive functions in simple tests in rested people and consistently better attention, planning and learning in more complex tasks. Under sleep deprivation, modafinil maintains wakefulness, memory and executive functions better than placebo. As an add-on to antidepressants, it improved mood and fatigue in a meta-analysis of 6 studies with 910 patients; there is no approval for this. The effect was seen in both unipolar and bipolar depression, and side effects did not occur more often than on placebo.
What the studies show
The shift worker study
209 people with shift work disorder took 200 mg of modafinil or placebo before each night shift for 3 months. Sleep latency in the night-time test lengthened by only 1.7 versus 0.3 minutes, but clinically 74 percent versus 36 percent were better. Accidents or near-accidents on the way home were reported by 29 percent versus 54 percent. Nonetheless, those treated remained markedly sleepy at night.
The meta-analysis on smart drugs
19 placebo-controlled studies examined single doses in adults without sleep deprivation. Across attention, executive functions, memory and processing speed, there was a significant but small effect, g = 0.10. There was no difference between 100 and 200 mg. The authors see only limited potential as a cognitive enhancer outside sleep deprivation.
The PET study
10 healthy men received modafinil or placebo, after which the occupancy of dopamine transporters in the brain was measured. Modafinil blocked about half of the transporters in the striatum and increased dopamine in the reward center. This moved it pharmacologically closer to classic stimulants.
Where the data stop
The question most users ask is the least studied: what does modafinil do for healthy, rested people who take it regularly over weeks or months? Almost all studies on performance enhancement test a single dose in the laboratory. The overall effect is small, and some studies even found worse creative, divergent thinking. A 2010 review concluded that expectations of modafinil exceed its actual effects. During prolonged sleep deprivation, repeated doses did not prevent the decline in performance; the participants possibly overestimated their own performance.
The risk of dependence is also unresolved. Germany removed modafinil from narcotics law in 2008 because clinical trials and ten years of market use had shown no signs of abuse. The PET data and the US classification as a controlled substance, however, point to a stimulant-like profile. The data on pregnancy are contradictory: a US registry found major malformations in 13.1 percent of live births versus 3 percent in the general population, while two French cohorts saw no significant increase. Developmental disorders in the children were not more frequent in one of these cohorts.
Status, approval and legal
In Germany, modafinil is an approved, prescription-only medicine. Following the EMA review, confirmed by the European Commission in January 2011, it is approved in the EU only for narcolepsy in adults; sleep apnea and shift work disorder were removed. Since 2008 it has no longer been a narcotic and can be prescribed on a regular prescription. In the US it is approved for three indications and controlled as a Schedule IV substance. Taking it for performance enhancement without a disease is off-label, obtaining it from abroad without a prescription bypasses medical oversight, and in one analysis gray-market tablets contained only 45.5 to 80.5 percent of the stated amount. In sports, modafinil is on the 2026 WADA list under S6.A as a non-specified stimulant and is prohibited in competition.
Safety
The most common side effects are headache, according to the US prescribing information in 34 percent versus 23 percent on placebo, and nausea in 11 versus 3 percent, plus nervousness, anxiety, insomnia and dizziness. Rare but serious are skin reactions up to Stevens-Johnson syndrome, which occurred more often in children, as well as psychiatric reactions up to psychosis, in some cases even at usual doses. Blood pressure and heart rhythm can rise or be disturbed. People with uncontrolled high blood pressure or cardiac arrhythmias, under-18s and pregnant women should not take it. Modafinil weakens hormonal contraceptives; according to the German prescribing information, additional contraception is needed for up to 2 months after stopping. People with pre-existing mental health conditions should be particularly cautious.
BK-Score Well supported, heavily overhyped
| Human evidence | 8 | |
|---|---|---|
| Mechanism | 8 | |
| Safety data | 9 | |
| Hype gap | 4 | |
| Track record of use | 9 |
Evidence 8, because the wakefulness-promoting effect is demonstrated in large double-blind RCTs with objective endpoints – narcolepsy with 283 and 271 patients (1998, 2000), shift work disorder with 209 patients and fewer accidents on the way home, 29 % versus 54 % (Czeisler, NEJM 2005) –, whereas for the performance enhancement in rested people sought in biohacking only a small effect from single-dose studies is available (g = 0.10 across 19 studies, Kredlow 2019); a 10 would be reserved for the approved indication narcolepsy. Mechanism 8, because the target structure has been quantified in humans: in PET, modafinil occupied 53.8 % of the dopamine transporters in the caudate nucleus and increased dopamine in the nucleus accumbens (Volkow, JAMA 2009), but the path from there to the cognitive effect has not been measured in detail. Safety 9, because long-term data from approval and pharmacovigilance have been available since 1998 and the EMA comprehensively reviewed the benefit-risk profile in 2011 (skin reactions, psychiatric and cardiovascular risks); data on pregnancy and on continuous use by healthy people remain open. Hype 4, because modafinil is regarded as a smart drug for more intelligence and productivity, while the meta-analyses show only small effects in rested people and Repantis 2010 writes that expectations exceed the actual effects. Use 9, because it has been on the market in the US since 1998 and in Germany had already been on the market for ten years by 2008, in each case under medical prescription. Direction positive: the effect on wakefulness is clearly established, the effect on cognition in healthy people is small but points the same way.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about modafinil
Does modafinil make you smarter?
Only a little. In rested people, a meta-analysis of 19 studies found a small effect on attention, memory and executive functions. In complex tasks and under sleep deprivation, the effect is more pronounced.
Is modafinil legal in Germany?
Modafinil is an approved, prescription-only medicine and has no longer been a narcotic since 2008. Modafinil is available only on a doctor’s prescription from a pharmacy; in the EU it is approved only for narcolepsy.
Is modafinil addictive?
In the approval trials there was no withdrawal after stopping, unlike with amphetamine. A PET study, however, showed that modafinil blocks dopamine transporters and increases dopamine in the reward center. The authors therefore advise caution in people prone to addiction.
What side effects does modafinil have?
The most common are headache, nausea, nervousness and sleep problems. Rare but serious are skin reactions such as Stevens-Johnson syndrome, psychiatric reactions and cardiovascular problems.
Does the pill still work with modafinil?
Modafinil weakens hormonal contraceptives. According to the German prescribing information, additional contraception should be used for up to 2 months after stopping.
Is modafinil banned in sports?
Yes, in competition. WADA lists modafinil in 2026 under S6.A as a non-specified stimulant.
Related
- Same sectionCBD (cannabidiol)
Sources
- US Modafinil in Narcolepsy Multicenter Study Group, Ann Neurol 1998 – narcolepsy RCT
- US Modafinil in Narcolepsy Multicenter Study Group, Neurology 2000 – narcolepsy RCT
- Czeisler et al., N Engl J Med 2005 – modafinil in shift work disorder
- Kredlow et al., J Clin Psychopharmacol 2019 – meta-analysis of modafinil as a cognitive enhancer
- Battleday and Brem, Eur Neuropsychopharmacol 2015 – neuroenhancement in healthy people
- Repantis et al., Pharmacol Res 2010 – modafinil and methylphenidate in healthy people
- Volkow et al., JAMA 2009 – modafinil and dopamine transporters in PET
- EMA – modafinil referral 2011
- FDA prescribing information Provigil (DailyMed)
- NADA – WADA Prohibited List 2026, informational German translation
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-04.